Questions about how individual parts of claim 1 might be changed. A question may describe something different from what the claim language recites, or a version of it; no view is offered on which.
1.1Reduced hepatic glucose production
What ifWhat if a biguanide controls fasting glucose by reducing hepatic glucose production?
Claim language“a KATP channel opener”
An oral metformin tablet delivers a biguanide that decreases hepatic glucose production, including glucose formed by gluconeogenesis. The resulting decrease in glucose released into the bloodstream lowers fasting glucose.
1.1Slower intestinal carbohydrate digestion
What ifWhat if an intestinal enzyme inhibitor reduces glucose excursions after meals?
Claim language“a KATP channel opener”
An oral acarbose tablet taken with the first bites of a meal inhibits alpha-glucosidase enzymes at the intestinal brush border. This slows the conversion of digestible carbohydrates into absorbable sugars and reduces the early postmeal glucose rise.
1.2Portioned carbohydrate at meals
What ifWhat if measured carbohydrate portions provide additional control of postmeal glucose?
Claim language“a magnesium supplement”
A meal plan assigns carbohydrate portions in grams, and a kitchen scale measures servings of starches and fruit. Replacing rapidly digested starches with intact grains and legumes slows carbohydrate digestion and reduces the early postmeal glucose rise.
1.2Postmeal walking sessions
What ifWhat if a scheduled walk after a meal provides additional control of postmeal glucose?
Claim language“a magnesium supplement”
A participant walks at a moderate pace after a meal, and a timer records the duration. Muscle contractions increase glucose uptake by skeletal muscle during the period when meal-derived glucose enters circulation.
Section 2 · machine-generated
Variations
Further arrangements of the same subject matter, described here as of the publication date at the foot of this page.
Other field of use
Paired oral dosing in veterinary research
A veterinary metabolic research unit uses the paired daily regimen in an animal model of the disorder. The KATP channel opener and magnesium supplement are prepared as separate oral suspensions in individually labeled dosing syringes. Staff administer both suspensions during the same daily handling session and record the delivered volumes and blood glucose measurements by animal identifier.
Component substitution
Hydrophilic cellulose matrix for the opener
An extended-release tablet contains diazoxide choline dispersed in a compressed hypromellose matrix in place of a polyethylene oxide matrix. Gastrointestinal fluid hydrates the outer layer, forming a gel through which the dissolved opener diffuses as the matrix erodes. A separate magnesium tablet supplies the daily supplement in the same administration session.
Magnesium citrate in an oral sachet
A unit-dose powder sachet contains magnesium citrate and a water-dispersible filler. The sachet fill mass is calculated from the assayed elemental magnesium content of the powder and the specified daily elemental magnesium amount. The sachet contents disperse in water for oral administration alongside a separate KATP channel opener tablet.
Parameter or scale variation
Fourteen daily pairs in one card
A 14-day blister card has two rows of 14 sealed cavities. Each column holds one daily unit of the KATP channel opener and one daily unit of the magnesium supplement. The user opens the two cavities in the matching column during a single daily administration session and repeats the sequence every 24 hours for 14 days.
Combination with existing systems
Paired dosing in barcode medication systems
An electronic medication administration record stores the KATP channel opener and magnesium supplement as two order lines linked to one daily administration event. Staff scan the patient wristband and the two unit-dose packages at the bedside. The system matches each package to its order line and marks the paired event complete after staff confirm administration of both components.
Automated or data-driven variant
Glucose profiles aligned to paired dosing
A continuous glucose monitor records interstitial glucose, and a medication logger records separate administration times for the KATP channel opener and magnesium supplement. Software converts both time streams to a common time base and aligns each day's glucose trace to the later of the two confirmed administration times. The software calculates glucose summaries for fixed intervals after the paired event and flags days with missing administration records or incomplete sensor coverage.
Specific version of a part
Diazoxide oral suspension
An aqueous suspension contains dispersed diazoxide particles and a suspending agent that slows settling. The container is shaken before measuring the prescribed volume, and the measured suspension is administered orally each day.
Magnesium oxide tablet
A compressed tablet contains magnesium oxide, a binder, and a disintegrant. The daily amount is expressed as elemental magnesium, and the tablet breaks apart after swallowing.
Magnesium citrate powder
A single-serving packet contains magnesium citrate powder, with its content specified as elemental magnesium per packet. The powder is mixed with water and taken orally as the daily serving.
Section 3 · quoted from USPTO records
Other work
Passages reproduced word for word from two earlier-published U.S. patent documents, placed beside the language of claim 1. No characterization is offered. Each passage is marked A or B for the document it comes from; ¶ numbers are the paragraph numbers in the USPTO’s published full text of that document.
1.1(i) a daily dose of a KATP channel opener, or a pharmaceutically acceptable salt thereof, and
In another embodiment, a KATP channel opener is administered to an overweight or obese individual as a solid oral dosage form administered from one, two, three or four times per 24 hours to induce weight loss at a daily dose of 50 to 275 mg.
A · US 2006/0051418 A1 · ¶ 287
1.2(ii) a daily dose of a magnesium supplement,
The magnesium powder is prepared as fine powder of 1000-1500 mesh. 30 g of powder is added into 100 pieces of commercial calcium supplements as the trace element additive, grounded and re-compressed into 100 tablets. 1 tablet per day should be taken for adults.
B · US 2017/0209486 A1 · ¶ 30
An empty cell means only that no passage was reproduced there.
Statements in these documents
The present invention relates to pharmaceutical formulations of potassium ATP (KATP) channel openers and their use for treatment of various diseases and conditions such as diabetes and obesity.
A · US 2006/0051418 A1 · ¶ 2
In this use, diazoxide acts to open potassium channels in vascular smooth muscle, stabilizing the membrane potential at the resting level, and preventing vascular smooth muscle contraction.
A · US 2006/0051418 A1 · ¶ 7
The present invention relates to the field of dietary supplement, and more particularly discloses a health-care preparation simultaneously with magnesium supplement and antioxidant functions.
B · US 2017/0209486 A1 · ¶ 2
Therefore, it is necessary to develop new magnesium supplements with no toxic or side effects, while at the same time have higher magnesium content and higher efficiency of absorption.
B · US 2017/0209486 A1 · ¶ 4
Cite aspatent.fyi, US 2026/0355232 A1, claim 1, first published 2026-11-19T09:44:02-05:00, https://patent.fyi/US20260355232/, SHA-256 d94a97e8e448e421e14b8bb3b30b060103f1554765fc699754e32e83def593bb